1. Phylogeny  
   IRAK4 is a member of the interleukin-1 receptor‐associated kinase (IRAK) family, a group of serine/threonine kinases that evolved from the ancestral kinase common to the Toll/Pelle family. In mammals, the IRAK family comprises IRAK-1, IRAK-2, IRAK-M (also known as IRAK-3), and IRAK4, with IRAK4 being the most recently identified and evolutionarily conserved member that bears the closest homology to the Drosophila Pelle protein (bahia2015interleukin1receptorassociated pages 3-4, li2002irak4anovel pages 1-2). IRAK4 is classified within the broader human kinome as a serine/threonine kinase; its evolutionary lineage can be traced to early metazoans, with orthologs found across diverse mammalian species, indicating its indispensable role in innate immune signaling (gosu2012molecularevolutionand pages 1-2, bahia2015interleukin1receptorassociated pages 2-3). Additionally, phylogenetic analyses situate IRAK4 within the core group of signal-transducing kinases that mediate Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling—factoring into the evolutionary conservation from invertebrates to vertebrates (kim2008theroleof pages 15-20).
2. Reaction Catalyzed  
   IRAK4 catalyzes the transfer of a phosphate group from ATP to serine and threonine residues on its substrate proteins. The general reaction can be written as: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺. This ATP-dependent phosphorylation reaction is an essential step in the propagation of signaling cascades initiated by IL-1R and various TLRs (bahia2015interleukin1receptorassociated pages 5-8, wang2009irak4inhibitorsfor pages 1-2).
3. Cofactor Requirements  
   The kinase activity of IRAK4 requires ATP as the phosphate donor and is dependent on divalent metal ion cofactors such as Mg²⁺. These cofactors facilitate proper binding of ATP to the catalytic site of the kinase domain and are essential for the phosphoryl transfer reaction (bahia2015interleukin1receptorassociated pages 4-5, wang2009irak4inhibitorsfor pages 3-4).
4. Substrate Specificity  
   IRAK4 phosphorylates serine/threonine residues on downstream signaling proteins in the IL-1R/TLR cascade, most notably on IRAK1 and on E3 ubiquitin ligases of the Pellino family (PELI1, PELI2, and PELI3). Although the precise consensus substrate motif for IRAK4 has not been fully defined, its substrate recognition appears to rely on the configuration of its kinase domain, which differentiates it from conventional kinases by presenting unique loop and helix conformations within the activation segment (bahia2015interleukin1receptorassociated pages 3-4, patra2016recentprogressin pages 10-12, wang2009irak4inhibitorsfor pages 4-6).
5. Structure  
   IRAK4 exhibits a well‐defined domain organization that is critical for its function. Its N-terminal region contains a death domain (DD) spanning approximately residues R20 to A104, which mediates protein–protein interactions necessary for recruitment to the Myddosome complex via the adaptor protein MyD88 (bahia2015interleukin1receptorassociated pages 3-4, li2002irak4anovel pages 3-5). Following the death domain, IRAK4 possesses a central kinase domain (approximately residues S186 to L454) that is responsible for its catalytic activity. This kinase domain displays a canonical serine/threonine kinase fold consisting of a smaller N-lobe—formed primarily of five antiparallel β-strands and an αC helix—and a larger C-lobe predominantly composed of α-helices. A unique feature of IRAK4 is its tyrosine residue (Tyr262) positioned in the ATP-binding pocket as the gatekeeper; this residue restricts access to a hydrophobic groove on the back of the pocket and distinguishes IRAK4 from many other kinases in the family (bahia2015interleukin1receptorassociated pages 4-5, wang2009irak4inhibitorsfor pages 3-4, kim2008theroleof pages 70-75). Activation loop autophosphorylation sites, including Thr342, Thr345, and Ser346, are present in the kinase domain and are critical for catalytic activation by stabilizing the active conformation (bahia2015interleukin1receptorassociated pages 4-5, patra2016recentprogressin pages 13-15). Structural studies, including high-resolution X-ray crystallographic analyses (e.g., PDB ID 2NRU), have confirmed these features and revealed conformational states corresponding to “helix C-in” active and “helix C-out” inactive forms (wang2009irak4inhibitorsfor pages 3-4, wang2019conformationalflexibilityand pages 2-3).
6. Regulation  
   Regulatory control of IRAK4 occurs primarily through post-translational modifications, most notably autophosphorylation within its activation loop. Autophosphorylation at Thr342, Thr345, and Ser346 is necessary for full catalytic activation and for establishing the proper conformation of the kinase domain, thereby facilitating substrate recognition and phosphoryl transfer (bahia2015interleukin1receptorassociated pages 4-5, patra2016recentprogressin pages 13-15, srikanth2024irak4autophosphorylationcontrols pages 1-4). In addition, IRAK4 signaling is modulated by its recruitment into the Myddosome complex via its death domain, where interactions with the MyD88 adaptor protein and possibly IRAK1 enhance its phosphorylation activity. This assembly is crucial for temporal and spatial regulation of kinase activity, ensuring that IRAK4 is activated only upon receptor engagement (bahia2015interleukin1receptorassociated pages 8-11, kim2008theroleof pages 70-75, srikanth2024irak4autophosphorylationcontrols pages 6-8). Although specific external kinases have not been identified as direct regulators of IRAK4 phosphorylation, its intrinsic autophosphorylation events constitute the primary mechanism of its activation. Furthermore, conformational changes within the kinase domain—such as the shifting of the αC helix and the DFG motif—serve as allosteric regulators that determine whether IRAK4 adopts an active or inactive state (wang2019conformationalflexibilityand pages 16-18, kim2008theroleof pages 81-86).
7. Function  
   IRAK4 plays a central role in initiating innate immune responses by acting as a proximal kinase in the TLR/IL-1R signaling pathways. Upon recognition of pathogen-associated molecular patterns (PAMPs) by TLRs or binding of interleukin-1 to its receptor, MyD88 is recruited to the activated receptor complex, and in turn, IRAK4 is rapidly brought into the so-called Myddosome complex (hynes2014advancesinthe pages 1-5, bahia2015interleukin1receptorassociated pages 2-3). In this assembled complex, IRAK4 phosphorylates IRAK1, which then undergoes autophosphorylation and ubiquitination; these modifications are essential for the recruitment of downstream molecules such as TRAF6 and the TAK1 complex. This signaling cascade culminates in the activation of the IKK complex and subsequent NF-κB nuclear translocation, leading to the induction of pro-inflammatory cytokines (bahia2015interleukin1receptorassociated pages 8-11, patra2016recentprogressin pages 1-3, kim2008theroleof pages 25-35). In addition to phosphorylating IRAK1, IRAK4 also phosphorylates E3 ubiquitin ligase members of the Pellino family, thereby promoting Pellino-mediated polyubiquitination events that further propagate the downstream signaling pathway (bahia2015interleukin1receptorassociated pages 2-3, patra2016recentprogressin pages 13-15). IRAK4 is broadly expressed in cells of the innate immune system, including macrophages, dendritic cells, and monocytes, and its functional importance is underscored by studies linking IRAK4 deficiency in humans to recurrent pyogenic bacterial infections during early childhood (hynes2014advancesinthe pages 1-5, suzuki2005irakskeyregulatory pages 1-2).
8. Other Comments  
   IRAK4 is a highly attractive therapeutic target for the development of small molecule inhibitors aimed at treating inflammatory and immune-related disorders. Numerous inhibitors, including ATP-competitive compounds, have been designed to specifically target the unique features of IRAK4’s ATP-binding pocket, particularly exploiting the presence of the tyrosine gatekeeper residue to achieve selectivity (wang2009irak4inhibitorsfor pages 12-12, seganish2016inhibitorsofinterleukin1 pages 22-26). Inhibitors of IRAK4 have shown promise in preclinical studies by effectively dampening excessive inflammatory responses in models of rheumatoid arthritis, systemic lupus erythematosus, and certain cancers driven by aberrant MyD88 signaling (patra2016recentprogressin pages 1-3, seganish2016inhibitorsofinterleukin1 pages 1-6). IRAK4 has also been implicated in conditions where its kinase activity modulates the stability of mRNAs encoding inflammatory cytokines, further substantiating its role in the regulation of immune responses (kim2008theroleof pages 81-86, pereira2023regulationofinnate pages 8-9). Known disease mutations in IRAK4, often resulting in loss-of-function phenotypes, lead to immunodeficiency syndromes characterized by heightened susceptibility to infections, while gain-of-function alterations or overactivation have been linked to autoimmune and oncologic disorders (bahia2015interleukin1receptorassociated pages 8-11, flannery2010theinterleukin1receptorassociated pages 20-24).
9. References
10. bahia2015interleukin1receptorassociated pages 3-4
11. bahia2015interleukin1receptorassociated pages 5-8
12. bahia2015interleukin1receptorassociated pages 8-11
13. hynes2014advancesinthe pages 1-5
14. kim2008theroleof pages 15-20
15. patra2016recentprogressin pages 10-12
16. patra2016recentprogressin pages 12-13
17. patra2016recentprogressin pages 3-6
18. srikanth2024irak4autophosphorylationcontrols pages 1-4
19. wang2009irak4inhibitorsfor pages 12-12
20. wang2009irak4inhibitorsfor pages 2-3
21. wang2009irak4inhibitorsfor pages 3-4
22. bahia2015interleukin1receptorassociated pages 2-3
23. bahia2015interleukin1receptorassociated pages 4-5
24. barbera2012activationmechanismsof pages 36-39
25. de2018mechanismofdysfunction pages 1-2
26. de2018mechanismofdysfunction pages 12-13
27. flannery2010theinterleukin1receptorassociated pages 20-24
28. flannery2010theinterleukin1receptorassociated pages 24-28
29. flannery2010theinterleukin1receptorassociated pages 43-47
30. gosu2012molecularevolutionand pages 1-2
31. gosu2012molecularevolutionand pages 14-15
32. kim2008theroleof pages 25-35
33. kim2008theroleof pages 58-64
34. kim2008theroleof pages 70-75
35. kim2008theroleof pages 81-86
36. kim2008theroleof pages 98-102
37. li2002irak4anovel pages 1-2
38. li2002irak4anovel pages 2-3
39. li2002irak4anovel pages 3-5
40. patra2016recentprogressin pages 1-3
41. patra2016recentprogressin pages 13-15
42. pereira2023regulationofinnate pages 8-9
43. seganish2016inhibitorsofinterleukin1 pages 1-6
44. seganish2016inhibitorsofinterleukin1 pages 22-26
45. srikanth2024irak4autophosphorylationcontrols pages 48-51
46. srikanth2024irak4autophosphorylationcontrols pages 6-8
47. suzuki2005irakskeyregulatory pages 1-2
48. suzuki2005irakskeyregulatory pages 6-7
49. vollmer2017themechanismof pages 1-3
50. wang2019conformationalflexibilityand pages 1-2
51. wang2019conformationalflexibilityand pages 16-18
52. wang2019conformationalflexibilityand pages 2-3
53. wang2019conformationalflexibilityand pages 8-10
54. chiang2011immunecomplexmediatedcell pages 1-2
55. flannery2010theinterleukin1receptorassociated pages 1-5

References

1. (bahia2015interleukin1receptorassociated pages 3-4): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
2. (bahia2015interleukin1receptorassociated pages 5-8): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
3. (bahia2015interleukin1receptorassociated pages 8-11): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
4. (hynes2014advancesinthe pages 1-5): John Hynes and Satheesh K. Nair. Advances in the discovery of small-molecule irak4 inhibitors. Annual Reports in Medicinal Chemistry, pages 117-133, Jan 2014. URL: https://doi.org/10.1016/b978-0-12-800167-7.00009-2, doi:10.1016/b978-0-12-800167-7.00009-2. This article has 35 citations and is from a peer-reviewed journal.
5. (patra2016recentprogressin pages 10-12): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
6. (patra2016recentprogressin pages 12-13): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
7. (patra2016recentprogressin pages 3-6): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
8. (srikanth2024irak4autophosphorylationcontrols pages 1-4): Niranjan Srikanth, Rafael Deliz-Aguirre, Deepika Kumari Gola, Margaux Bilay, Elke Ziska, and Marcus J. Taylor. Irak4 autophosphorylation controls inflammatory signaling by activating irak oligomerization. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2023.12.21.572799, doi:10.1101/2023.12.21.572799. This article has 1 citations.
9. (wang2009irak4inhibitorsfor pages 12-12): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
10. (wang2009irak4inhibitorsfor pages 2-3): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
11. (wang2009irak4inhibitorsfor pages 3-4): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
12. (bahia2015interleukin1receptorassociated pages 2-3): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
13. (bahia2015interleukin1receptorassociated pages 4-5): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
14. (barbera2012activationmechanismsof pages 36-39): E Mendoza Barberá. Activation mechanisms of the innate immune system structure-function studies of interactions between death domains of myd88 and irak proteins. Unknown journal, 2012.
15. (de2018mechanismofdysfunction pages 1-2): Saurav De, Fawziya Karim, Ezechielle Kiessu, Leah Cushing, Lih-Ling Lin, Pegah Ghandil, Cyrille Hoarau, Jean-Laurent Casanova, Anne Puel, and Vikram R. Rao. Mechanism of dysfunction of human variants of the irak4 kinase and a role for its kinase activity in interleukin-1 receptor signaling. Journal of Biological Chemistry, 293:15208-15220, Sep 2018. URL: https://doi.org/10.1074/jbc.ra118.003831, doi:10.1074/jbc.ra118.003831. This article has 44 citations and is from a domain leading peer-reviewed journal.
16. (de2018mechanismofdysfunction pages 12-13): Saurav De, Fawziya Karim, Ezechielle Kiessu, Leah Cushing, Lih-Ling Lin, Pegah Ghandil, Cyrille Hoarau, Jean-Laurent Casanova, Anne Puel, and Vikram R. Rao. Mechanism of dysfunction of human variants of the irak4 kinase and a role for its kinase activity in interleukin-1 receptor signaling. Journal of Biological Chemistry, 293:15208-15220, Sep 2018. URL: https://doi.org/10.1074/jbc.ra118.003831, doi:10.1074/jbc.ra118.003831. This article has 44 citations and is from a domain leading peer-reviewed journal.
17. (flannery2010theinterleukin1receptorassociated pages 20-24): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
18. (flannery2010theinterleukin1receptorassociated pages 24-28): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
19. (flannery2010theinterleukin1receptorassociated pages 43-47): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
20. (gosu2012molecularevolutionand pages 1-2): Vijayakumar Gosu, Shaherin Basith, Prasannavenkatesh Durai, and Sangdun Choi. Molecular evolution and structural features of irak family members. PLoS ONE, 7:e49771, Nov 2012. URL: https://doi.org/10.1371/journal.pone.0049771, doi:10.1371/journal.pone.0049771. This article has 64 citations and is from a peer-reviewed journal.
21. (gosu2012molecularevolutionand pages 14-15): Vijayakumar Gosu, Shaherin Basith, Prasannavenkatesh Durai, and Sangdun Choi. Molecular evolution and structural features of irak family members. PLoS ONE, 7:e49771, Nov 2012. URL: https://doi.org/10.1371/journal.pone.0049771, doi:10.1371/journal.pone.0049771. This article has 64 citations and is from a peer-reviewed journal.
22. (kim2008theroleof pages 15-20): TW Kim. The role of kinase activity of irak4 in tlr/il-1r-mediated signaling. Unknown journal, 2008.
23. (kim2008theroleof pages 25-35): TW Kim. The role of kinase activity of irak4 in tlr/il-1r-mediated signaling. Unknown journal, 2008.
24. (kim2008theroleof pages 58-64): TW Kim. The role of kinase activity of irak4 in tlr/il-1r-mediated signaling. Unknown journal, 2008.
25. (kim2008theroleof pages 70-75): TW Kim. The role of kinase activity of irak4 in tlr/il-1r-mediated signaling. Unknown journal, 2008.
26. (kim2008theroleof pages 81-86): TW Kim. The role of kinase activity of irak4 in tlr/il-1r-mediated signaling. Unknown journal, 2008.
27. (kim2008theroleof pages 98-102): TW Kim. The role of kinase activity of irak4 in tlr/il-1r-mediated signaling. Unknown journal, 2008.
28. (li2002irak4anovel pages 1-2): Shyun Li, Astrid Strelow, Elizabeth J. Fontana, and Holger Wesche. Irak-4: a novel member of the irak family with the properties of an irak-kinase. Proceedings of the National Academy of Sciences, 99:5567-5572, Apr 2002. URL: https://doi.org/10.1073/pnas.082100399, doi:10.1073/pnas.082100399. This article has 960 citations.
29. (li2002irak4anovel pages 2-3): Shyun Li, Astrid Strelow, Elizabeth J. Fontana, and Holger Wesche. Irak-4: a novel member of the irak family with the properties of an irak-kinase. Proceedings of the National Academy of Sciences, 99:5567-5572, Apr 2002. URL: https://doi.org/10.1073/pnas.082100399, doi:10.1073/pnas.082100399. This article has 960 citations.
30. (li2002irak4anovel pages 3-5): Shyun Li, Astrid Strelow, Elizabeth J. Fontana, and Holger Wesche. Irak-4: a novel member of the irak family with the properties of an irak-kinase. Proceedings of the National Academy of Sciences, 99:5567-5572, Apr 2002. URL: https://doi.org/10.1073/pnas.082100399, doi:10.1073/pnas.082100399. This article has 960 citations.
31. (patra2016recentprogressin pages 1-3): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
32. (patra2016recentprogressin pages 13-15): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
33. (pereira2023regulationofinnate pages 8-9): Milton Pereira and Ricardo T. Gazzinelli. Regulation of innate immune signaling by irak proteins. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133354, doi:10.3389/fimmu.2023.1133354. This article has 53 citations and is from a peer-reviewed journal.
34. (seganish2016inhibitorsofinterleukin1 pages 1-6): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
35. (seganish2016inhibitorsofinterleukin1 pages 22-26): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
36. (srikanth2024irak4autophosphorylationcontrols pages 48-51): Niranjan Srikanth, Rafael Deliz-Aguirre, Deepika Kumari Gola, Margaux Bilay, Elke Ziska, and Marcus J. Taylor. Irak4 autophosphorylation controls inflammatory signaling by activating irak oligomerization. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2023.12.21.572799, doi:10.1101/2023.12.21.572799. This article has 1 citations.
37. (srikanth2024irak4autophosphorylationcontrols pages 6-8): Niranjan Srikanth, Rafael Deliz-Aguirre, Deepika Kumari Gola, Margaux Bilay, Elke Ziska, and Marcus J. Taylor. Irak4 autophosphorylation controls inflammatory signaling by activating irak oligomerization. bioRxiv, Feb 2024. URL: https://doi.org/10.1101/2023.12.21.572799, doi:10.1101/2023.12.21.572799. This article has 1 citations.
38. (suzuki2005irakskeyregulatory pages 1-2): Nobutaka Suzuki, Shinobu Suzuki, and Takashi Saito. Iraks: key regulatory kinases of innate immunity. Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, 4:13-20, Feb 2005. URL: https://doi.org/10.2174/1568014053005345, doi:10.2174/1568014053005345. This article has 15 citations.
39. (suzuki2005irakskeyregulatory pages 6-7): Nobutaka Suzuki, Shinobu Suzuki, and Takashi Saito. Iraks: key regulatory kinases of innate immunity. Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, 4:13-20, Feb 2005. URL: https://doi.org/10.2174/1568014053005345, doi:10.2174/1568014053005345. This article has 15 citations.
40. (vollmer2017themechanismof pages 1-3): Stefan Vollmer, Sam Strickson, Tinghu Zhang, Nathanael Gray, Katherine L. Lee, Vikram R. Rao, and Philip Cohen. The mechanism of activation of irak1 and irak4 by interleukin-1 and toll-like receptor agonists. Biochemical Journal, 474:2027-2038, Jun 2017. URL: https://doi.org/10.1042/bcj20170097, doi:10.1042/bcj20170097. This article has 105 citations and is from a domain leading peer-reviewed journal.
41. (wang2009irak4inhibitorsfor pages 1-2): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
42. (wang2009irak4inhibitorsfor pages 4-6): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
43. (wang2019conformationalflexibilityand pages 1-2): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.
44. (wang2019conformationalflexibilityand pages 16-18): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.
45. (wang2019conformationalflexibilityand pages 2-3): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.
46. (wang2019conformationalflexibilityand pages 8-10): Li Wang, Ryan Ferrao, Qiubai Li, John M. Hatcher, Hwan Geun Choi, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (irak4). Journal of Biological Chemistry, 294:4511-4519, Mar 2019. URL: https://doi.org/10.1074/jbc.ra118.005428, doi:10.1074/jbc.ra118.005428. This article has 18 citations and is from a domain leading peer-reviewed journal.
47. (chiang2011immunecomplexmediatedcell pages 1-2): Eugene Y Chiang, Xin Yu, and Jane L Grogan. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for irak1/4 kinase activity across human cell types. The Journal of Immunology, 186:1279-1288, Jan 2011. URL: https://doi.org/10.4049/jimmunol.1002821, doi:10.4049/jimmunol.1002821. This article has 89 citations.
48. (flannery2010theinterleukin1receptorassociated pages 1-5): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.